NCT03264391 is a clinical trial in Retinal Vasculitis, sponsored by Assiut University.

Who is sponsoring NCT03264391?

NCT03264391 is sponsored by Assiut University.

What condition does NCT03264391 study?

NCT03264391 studies Retinal Vasculitis, Behcet Syndrome.

Is NCT03264391 still recruiting?

NCT03264391 is currently completed. Last updated 13 January 2021.

Last reviewed 2021-01-13 · How we verify

NCT03264391

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography

Completed Last updated 13 January 2021

What this trial tests

trial in Retinal Vasculitis in 30 participants. Completed in 31 January 2020.

Timeline

1 March 2018

Primary endpoint
30 December 2019

31 January 2020

Quick facts

Lead sponsor	Assiut University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 March 2018
Primary completion	30 December 2019
Estimated completion	31 January 2020
Sites	1 location across Egypt

Conditions studied

Retinal Vasculitis — all drugs for Retinal Vasculitis →
Behcet Syndrome — all drugs for Behcet Syndrome →

Sponsor

Assiut University

Who can join

18 and older, any sex, with Retinal Vasculitis or Behcet Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Behcet's disease is an important cause of retinal vasculitis and vision loss in Egypt. Fluorescein angiography is the standard method of diagnosis of retinal vasculitis. OCT angiography (OCT-A) is a recently developed method that can be used in the evaluation of retinal circulation. In this study, we will test the utility of OCT-A in diagnosis and follow up of retinal vascular changes in cases diagnosed with Behcet's disease that visit the outpatient uveitis clinic of Assiut University hospital, a major tertiary center in southern Egypt, over a one year duration. Also, correlation of OCT-A changes with visual acuity and hence prognosis will be described.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03264391 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 13 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03264391.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing